ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test reut.rs/4vmkwNM
ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test
ALZpath said on Wednesday it had signed a global licensing agreement with Abbott Laboratories to help advance blood-based testing for Alzheimer's disease, as companies race to offer easier-to-use diagnostic options for the brain-wasting disease.
reut.rs
June 24, 2026 at 11:40 AM
ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test reut.rs/4vmkwNM
ALZpath said on Wednesday it had signed a global licensing agreement with Abbott Laboratories to help advance blood-based testing for Alzheimer's disease, as companies race to offer easier-to-use diagnostic options for the brain-wasting disease.
ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test
ALZpath said on Wednesday it had signed a global licensing agreement with Abbott Laboratories to help advance blood-based testing for Alzheimer's disease, as companies race to offer easier-to-use diagnostic options for the brain-wasting disease.
reut.rs
June 24, 2026 at 12:01 PM
ALZpath said on Wednesday it had signed a global licensing agreement with Abbott Laboratories to help advance blood-based testing for Alzheimer's disease, as companies race to offer easier-to-use diagnostic options for the brain-wasting disease.
Neurocode USA's ALZpath Assay Marks a Breakthrough in Alzheimer's Diagnostics#USA#Bellingham#Alzheimer's#Neurocode#ALZpath
Neurocode USA's ALZpath Assay Marks a Breakthrough in Alzheimer's Diagnostics
Neurocode USA has unveiled remarkable results showcasing the ALZpath pTau217 assay's effectiveness in Alzheimer's diagnosis, surpassing traditional methods.
third-news.com
January 28, 2025 at 2:27 PM
Neurocode USA's ALZpath Assay Marks a Breakthrough in Alzheimer's Diagnostics#USA#Bellingham#Alzheimer's#Neurocode#ALZpath
ALZpath Recognized as One of the World's Top Innovators by Fast Company in 2025#USA#Alzheimer's_Disease#Carlsbad#Fast_Company#ALZpath
ALZpath Recognized as One of the World's Top Innovators by Fast Company in 2025
ALZpath has made it to Fast Company's list of the Most Innovative Companies of 2025 for its groundbreaking diagnostics for Alzheimer's disease.
third-news.com
March 18, 2025 at 11:22 AM
ALZpath Recognized as One of the World's Top Innovators by Fast Company in 2025#USA#Alzheimer's_Disease#Carlsbad#Fast_Company#ALZpath
ALZpath Wins 2025 Edison Bronze Award for Innovative Alzheimer's Testing Solution#USA#Carlsbad#ALZpath#Edison_Award#pTau217_Antibody
ALZpath Wins 2025 Edison Bronze Award for Innovative Alzheimer's Testing Solution
ALZpath, a leader in Alzheimer's diagnostics, is awarded the 2025 Bronze Edison Award for its pTau217 antibody, essential for early detection of Alzheimer's disease.
third-news.com
April 7, 2025 at 12:34 PM
ALZpath Wins 2025 Edison Bronze Award for Innovative Alzheimer's Testing Solution#USA#Carlsbad#ALZpath#Edison_Award#pTau217_Antibody
At this year’s #AAIC25, ALZpath CEO Mike Banville joined NeurologyLive to discuss how the ALZpath proprietary #pTau217 antibody is powering blood-based testing to enable earlier, scalable Alzheimer’s disease detection. 🧠💜
📌Watch the full interview here: www.neurologylive.com/view/expandi...
📌Watch the full interview here: www.neurologylive.com/view/expandi...
Expanding the Presence of the ALZpath Blood Test in Alzheimer Disease Research: Mike Banville
At AAIC 2025, the chief executive officer at ALZpath discussed the growing adoption of the company’s pTau217 antibody blood test for AD research, emphasizing its potential role in early detection. [WA...
neurologylive.com
August 27, 2025 at 4:33 PM
At this year’s #AAIC25, ALZpath CEO Mike Banville joined NeurologyLive to discuss how the ALZpath proprietary #pTau217 antibody is powering blood-based testing to enable earlier, scalable Alzheimer’s disease detection. 🧠💜
📌Watch the full interview here: www.neurologylive.com/view/expandi...
📌Watch the full interview here: www.neurologylive.com/view/expandi...
We’re thrilled to share that Basecamp Research has been named to Fast Company’s 2025 World’s Most Innovative Companies list! 🚀
A huge thank you to our incredible team, partners, and the wider scientific community who support our mission.
Read more here: bit.ly/43S6CrF
#FCMostInnovative
A huge thank you to our incredible team, partners, and the wider scientific community who support our mission.
Read more here: bit.ly/43S6CrF
#FCMostInnovative
March 18, 2025 at 11:35 AM
We’re thrilled to share that Basecamp Research has been named to Fast Company’s 2025 World’s Most Innovative Companies list! 🚀
A huge thank you to our incredible team, partners, and the wider scientific community who support our mission.
Read more here: bit.ly/43S6CrF
#FCMostInnovative
A huge thank you to our incredible team, partners, and the wider scientific community who support our mission.
Read more here: bit.ly/43S6CrF
#FCMostInnovative
Significant Advances in Alzheimer's Diagnostics with ALZpath's pTau217 Antibody at AAIC#United_States#Alzheimer's#Carlsbad#ALZpath#pTau217
Significant Advances in Alzheimer's Diagnostics with ALZpath's pTau217 Antibody at AAIC
At the AAIC conference, ALZpath highlights breakthroughs involving its pTau217 antibody for Alzheimer's diagnostics and treatment development.
third-news.com
July 28, 2025 at 12:41 PM
Significant Advances in Alzheimer's Diagnostics with ALZpath's pTau217 Antibody at AAIC#United_States#Alzheimer's#Carlsbad#ALZpath#pTau217
ALZpath featured in Reuters following announcement of global licensing agreement with Abbott, helping advance blood-based Alzheimer’s disease testing worldwide.
🔗Read more: www.reuters.com/world/alzpat...
#AlzheimersDisease #pTau217 #Diagnostics
🔗Read more: www.reuters.com/world/alzpat...
#AlzheimersDisease #pTau217 #Diagnostics
ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test
ALZpath said on Wednesday it had signed a global licensing agreement with Abbott Laboratories to help advance blood-based testing for Alzheimer's disease, as companies race to offer easier-to-use di...
www.reuters.com
June 25, 2026 at 9:25 PM
ALZpath featured in Reuters following announcement of global licensing agreement with Abbott, helping advance blood-based Alzheimer’s disease testing worldwide.
🔗Read more: www.reuters.com/world/alzpat...
#AlzheimersDisease #pTau217 #Diagnostics
🔗Read more: www.reuters.com/world/alzpat...
#AlzheimersDisease #pTau217 #Diagnostics
Just 1 week until #AAIC26.
ALZpath is looking forward to attending AAIC 2026 next week in London.
If you’re attending, we welcome the opportunity to connect. To schedule a time with the ALZpath team, reach out to Jacob Hunter at jacob@alzpath.bio or message us here directly.
See you in London.
ALZpath is looking forward to attending AAIC 2026 next week in London.
If you’re attending, we welcome the opportunity to connect. To schedule a time with the ALZpath team, reach out to Jacob Hunter at jacob@alzpath.bio or message us here directly.
See you in London.
July 6, 2026 at 4:11 PM
Just 1 week until #AAIC26.
ALZpath is looking forward to attending AAIC 2026 next week in London.
If you’re attending, we welcome the opportunity to connect. To schedule a time with the ALZpath team, reach out to Jacob Hunter at jacob@alzpath.bio or message us here directly.
See you in London.
ALZpath is looking forward to attending AAIC 2026 next week in London.
If you’re attending, we welcome the opportunity to connect. To schedule a time with the ALZpath team, reach out to Jacob Hunter at jacob@alzpath.bio or message us here directly.
See you in London.
Plasma p-tau217 in Alzheimer disease: Lumipulse and ALZpath SIMOA head-to-head comparison https://www.medrxiv.org/content/10.1101/2024.05.02.24306780v1
Plasma p-tau217 in Alzheimer disease: Lumipulse and ALZpath SIMOA head-to-head comparison https://www.medrxiv.org/content/10.1101/2024.05.02.24306780v1
Background: Plasma phosphorylated ptau217 (ptau217) has been shown to be one of the most accurate di
www.medrxiv.org
May 4, 2024 at 5:27 AM
Plasma p-tau217 in Alzheimer disease: Lumipulse and ALZpath SIMOA head-to-head comparison https://www.medrxiv.org/content/10.1101/2024.05.02.24306780v1
ALZpath's pTau217 Antibody Triumphs at BioTech Breakthrough Awards for Diagnostics Innovation#USA#Carlsbad#ALZpath#pTau217#Alzheimer
ALZpath's pTau217 Antibody Triumphs at BioTech Breakthrough Awards for Diagnostics Innovation
ALZpath's pTau217 antibody has been awarded 'Diagnostics Innovation of the Year,' enhancing early Alzheimer’s detection capabilities globally.
third-news.com
November 6, 2025 at 2:09 PM
ALZpath's pTau217 Antibody Triumphs at BioTech Breakthrough Awards for Diagnostics Innovation#USA#Carlsbad#ALZpath#pTau217#Alzheimer
Recursion named among Top 5 biotechs in @fastcompany.com’s 2025 Most Innovative Companies List for "mapping a path for AI-driven drug discovery.” @adambluestein.bsky.social: “Recursion was a #TechBio company before there was such a thing.“ www.fastcompany.com/91269109/bio...
These 10 biotech companies are changing how we discover new drugs and treat complex diseases
Why ALZpath, GeneDX, 10x Genomics, Protagonist Therapeutics, and Recursion are among the most innovative biotech companies of 2025.
www.fastcompany.com
March 19, 2025 at 1:27 PM
Recursion named among Top 5 biotechs in @fastcompany.com’s 2025 Most Innovative Companies List for "mapping a path for AI-driven drug discovery.” @adambluestein.bsky.social: “Recursion was a #TechBio company before there was such a thing.“ www.fastcompany.com/91269109/bio...
ALZpath Enhances Strategic Partnership with Alamar Biosciences for Alzheimer's Diagnostics#United_States#Carlsbad#Alamar_Biosciences#ALZpath#pTau217
ALZpath Enhances Strategic Partnership with Alamar Biosciences for Alzheimer's Diagnostics
ALZpath, Inc. has advanced its strategic agreement with Alamar Biosciences to include clinical diagnostics for Alzheimer's, utilizing innovative blood tests.
third-news.com
July 23, 2026 at 12:44 PM
ALZpath Enhances Strategic Partnership with Alamar Biosciences for Alzheimer's Diagnostics#United_States#Carlsbad#Alamar_Biosciences#ALZpath#pTau217
ALZpath Showcases Global Clinical Contributions at AAIC 2026 with pTau217 Antibody#United_States#Carlsbad#ALZpath#pTau217#AAIC2026
ALZpath Showcases Global Clinical Contributions at AAIC 2026 with pTau217 Antibody
ALZpath, Inc. highlights its pTau217 antibody in 86 presentations at AAIC 2026, showcasing its diagnostic significance in Alzheimer's disease research.
third-news.com
July 13, 2026 at 8:38 AM
ALZpath Showcases Global Clinical Contributions at AAIC 2026 with pTau217 Antibody#United_States#Carlsbad#ALZpath#pTau217#AAIC2026
July 8, 2026 at 11:17 PM
4/🧵In addition, plasma p-tau217 Lilly and p-tau181 Lilly discriminated AD from ALS with higher accuracy than p-tau217 ALZpath and p-tau181 UGOT (AUCs 0.89-0.91 vs 0.54-0.74, respectively).
May 5, 2025 at 12:31 PM
4/🧵In addition, plasma p-tau217 Lilly and p-tau181 Lilly discriminated AD from ALS with higher accuracy than p-tau217 ALZpath and p-tau181 UGOT (AUCs 0.89-0.91 vs 0.54-0.74, respectively).
3/🧵Increases in AD vs ALS were significantly larger for the LMW-specific plasma assays (p-tau217 Lilly: 148.6%; p-tau181 Lilly: 86.5%) than the respective non-LMW-specific assays (p-tau217 ALZpath: 69.9%; p-tau181 UGOT-3.7%).
May 5, 2025 at 12:31 PM
3/🧵Increases in AD vs ALS were significantly larger for the LMW-specific plasma assays (p-tau217 Lilly: 148.6%; p-tau181 Lilly: 86.5%) than the respective non-LMW-specific assays (p-tau217 ALZpath: 69.9%; p-tau181 UGOT-3.7%).
2/🧵Increases in ALS vs controls were significantly smaller for the LMW-specific plasma p-tau assays (p-tau217 Lilly: 20.5%; p-tau181 Lilly: 15.9%) compared with respective assays that also detect HMW p-tau (p-tau217 ALZpath: 121.3%; p-tau181 UGOT: 92.0%).
May 5, 2025 at 12:31 PM
2/🧵Increases in ALS vs controls were significantly smaller for the LMW-specific plasma p-tau assays (p-tau217 Lilly: 20.5%; p-tau181 Lilly: 15.9%) compared with respective assays that also detect HMW p-tau (p-tau217 ALZpath: 121.3%; p-tau181 UGOT: 92.0%).